Literature DB >> 26221893

A case of abdominal pain with dyslipidemia: difficulties diagnosing cholesterol ester storage disease.

S J Cameron1, U Daimee1, R C Block2.   

Abstract

Cholesterol ester storage disease is an exceptionally rare dyslipidemia with less than 150 cases reported in the medical literature. The diagnosis of Cholesterol Ester Storage Disease is often missed by virtue of the fact that the symptoms mimic both inborn metabolic defects and hepatic steatosis. Patients with Cholesterol Ester Storage Disease usually present with atypical complaints including abdominal pain from altered gut motility. Blood analysis typically reveals abnormal liver function tests with coincident dyslipidemia. We present a case of a young woman with Cholesterol Ester Storage Disease who was followed over two decades. We discuss issues common to her initial protracted diagnosis with management options over time.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26221893      PMCID: PMC5096402     

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  22 in total

1.  Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency.

Authors:  L Leone; P F Ippoliti; R Antonicelli
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

2.  Combined hyperlipidaemia as a presenting sign of cholesteryl ester storage disease.

Authors:  S Decarlis; C Agostoni; F Ferrante; S Scarlino; E Riva; M Giovannini
Journal:  J Inherit Metab Dis       Date:  2009-02-15       Impact factor: 4.982

Review 3.  Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis.

Authors:  Tim Reynolds
Journal:  J Clin Pathol       Date:  2013-09-02       Impact factor: 3.411

4.  Severe chronic diarrhea and weight loss in cholesteryl ester storage disease: a case report.

Authors:  Uta Drebber; Matthias Andersen; Hans U Kasper; Peter Lohse; Manfred Stolte; Hans P Dienes
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

5.  Structural bases of Wolman disease and cholesteryl ester storage disease.

Authors:  Seiji Saito; Kazuki Ohno; Toshihiro Suzuki; Hitoshi Sakuraba
Journal:  Mol Genet Metab       Date:  2011-11-20       Impact factor: 4.797

6.  Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation.

Authors:  S vom Dahl; K Harzer; A Rolfs; B Albrecht; C Niederau; C Vogt; S van Weely; J Aerts; G Müller; D Häussinger
Journal:  J Hepatol       Date:  1999-10       Impact factor: 25.083

7.  New lysosomal acid lipase gene mutants explain the phenotype of Wolman disease and cholesteryl ester storage disease.

Authors:  F Pagani; R Pariyarath; R Garcia; C Stuani; A B Burlina; G Ruotolo; M Rabusin; F E Baralle
Journal:  J Lipid Res       Date:  1998-07       Impact factor: 5.922

8.  Safety and efficacy of treatment of pediatric cholesteryl ester storage disease with lovastatin.

Authors:  C J Glueck; P Lichtenstein; T Tracy; J Speirs
Journal:  Pediatr Res       Date:  1992-11       Impact factor: 3.756

9.  Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity.

Authors:  C Aslanidis; S Ries; P Fehringer; C Büchler; H Klima; G Schmitz
Journal:  Genomics       Date:  1996-04-01       Impact factor: 5.736

Review 10.  Ezetimibe therapy: mechanism of action and clinical update.

Authors:  Binh An P Phan; Thomas D Dayspring; Peter P Toth
Journal:  Vasc Health Risk Manag       Date:  2012-07-03
View more
  1 in total

1.  Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency.

Authors:  Maja Di Rocco; Livia Pisciotta; Annalisa Madeo; Marta Bertamino; Stefano Bertolini
Journal:  Orphanet J Rare Dis       Date:  2018-01-27       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.